/Company Directory

/

Asset Brief

OmniCAR (HER2+)

PTX·Prescient Therapeutics·HER2-positive solid tumours·Preclinical

auto_awesomeAuto-generated competitive-context view. No editorial brief has been written for OmniCAR (HER2+) yet — the sections below are built from the competitor corpus, ASX filings, and ClinicalTrials.gov. The plain-language brief and trial-design summary appear once an analyst curates this asset.

Class Catalyst Calendar

What's landed, what's next for OmniCAR (HER2+) and peers

OmniCAR (HER2+)'s own upcoming catalysts alongside class-defining historical readouts and upcoming primary completion dates in the same mechanism classes. Each event moves the broader thesis for OmniCAR (HER2+). Showing past 6 months and next 12 months · 11 later hidden.

ConferenceAACR Annual Meeting 2026· ChicagoApr 2026
ConferenceASCO Annual Meeting 2026· ChicagoMay 2026
Today
Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer

Trial design comparison

How OmniCAR (HER2+) reads against active peer trials

Same axes, same units. Discontinued and historical pivotal trials excluded; see Competitor Landscape below for the full set.

Trial	Sponsor	Class	Phase / Line	Design	Primary endpoint	Dosing	Key eligibility	n
OmniCAR (HER2+)	Prescient Therapeutics	HER2 CAR-T (adapter platform)	Preclinical					0
To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer	SUNHO（China）BioPharmaceutical CO., Ltd.	Small Molecule Other

Competitor Landscape

Competing programmes by mechanism and phase

Read-across commentary attached per trial. Phase ordering preserved within each group.

Mechanism trade-offs· 1 classes comparedexpand ›

Mechanism	Speed to patient	Manufacturing	Best approved result	Durability	Moat
Fc Fusion ProteinFc-fusion trap	Off-the-shelf	Biologic	Eylea / Vabysmo class	Dosing-interval driven	High (incumbents)

Small Molecule OtherASX peers ›

Curated Commentary

Third-party coverage(none curated yet)

expand ›

External analyst notes, journalism, and industry commentary cited with attribution.

No third-party coverage curated for OmniCAR (HER2+) yet. Broker coverage of Prescient Therapeutics is thin; named analyst notes will appear here as they become available. For now, see the company's ASX announcements and the linked sponsor / class sources elsewhere on this page.

OmniCAR (HER2+)n = 0

Prescient Therapeutics·HER2 CAR-T (adapter platform)·Preclinical

Design
Primary endpoint
Dosing
Eligibility

To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancern = —

SUNHO（China）BioPharmaceutical CO., Ltd.·Small Molecule Other·PHASE2/PHASE3

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutationsn = —

Cancer Research UK·Monoclonal antibody·PHASE2/PHASE3

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q)n = —

National Cancer Institute (NCI)·Antibody-drug conjugate·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B)n = —

National Cancer Institute (NCI)·Kinase Inhibitor·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)n = —

National Cancer Institute (NCI)·Monoclonal antibody·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutationsn = —

AstraZeneca·Antibody-drug conjugate·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterationsn = —

Seagen, a wholly owned subsidiary of Pfizer·Kinase Inhibitor·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)n = —

Astellas Pharma Global Development, Inc.·Antibody-drug conjugate·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumorsn = —

AstraZeneca·Antibody-drug conjugate·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

SHR-4602 for Injection in Subjects With HER2-expressing or -Mutated Unresectable or Metastatic Solid Tumorsn = —

Jiangsu HengRui Medicine Co., Ltd.·Kinase Inhibitor·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Neratinib Tablets Monotherapy for Advanced Solid Tumors With HER2 Mutationsn = —

Convalife (Shanghai) Co., Ltd.·Kinase Inhibitor·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2n = —

Seagen, a wholly owned subsidiary of Pfizer·Antibody-drug conjugate·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

SSGJ-705 Monotherapy and Combination Therapy in Advanced HER2-Expressing Solid Tumorsn = —

Shenyang Sunshine Pharmaceutical Co., LTD.·Small Molecule Other·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumorsn = —

Jazz Pharmaceuticals·Monoclonal antibody·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancersn = —

Memorial Sloan Kettering Cancer Center·Antibody-drug conjugate·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)n = —

Bayer·Kinase Inhibitor·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)n = —

National Cancer Institute (NCI)·Kinase Inhibitor·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)n = —

M.D. Anderson Cancer Center·Antibody-drug conjugate·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumorsn = —

AstraZeneca·Antibody-drug conjugate·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancern = —

ALX Oncology Inc.·Fc Fusion Protein·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterationsn = —

Boehringer Ingelheim·Kinase Inhibitor·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Clinical Trial Evaluating the Activity of Zanidatamab for the Treatment of Patients With Solid Tumors With an Alteration of the HER2 Gene.n = —

UNICANCER·Monoclonal antibody·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)n = —

Daiichi Sankyo·Antibody-drug conjugate·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumorsn = —

Seagen, a wholly owned subsidiary of Pfizer·Antibody-drug conjugate·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

A Study of MRG002 in Patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancern = —

Shanghai Miracogen Inc.·Bispecific Other·PHASE1/PHASE2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

HER2 Targeted HypoSti.CAR-T Cells in HER2 Positive Advanced Solid Tumorsn = —

Chinese PLA General Hospital·HER2 CAR-T (adapter platform)·PHASE1/PHASE2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignanciesn = —

BicycleTx Limited·Bispecific Other·PHASE1/PHASE2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumorsn = —

DualityBio Inc.·Bispecific Other·PHASE1/PHASE2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumorsn = —

Gilead Sciences·Antibody-drug conjugate·PHASE1/PHASE2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancern = —

Phoenix Molecular Designs·Kinase Inhibitor·PHASE1/PHASE2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alterationn = —

ORIC Pharmaceuticals·Kinase Inhibitor·PHASE1/PHASE2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

A Trial of SHR-A1811 Combined With Other Antitumor Therapies in Advanced Solid Tumors.n = —

Jiangsu HengRui Medicine Co., Ltd.·Monoclonal antibody·PHASE1/PHASE2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

A Study of BL-M07D1 in Patients With a Variety of Solid Tumors Including Locally Advanced or Metastatic HER2-positive/Low-expressing Urinary and Gastrointestinal Tumorsn = —

Sichuan Baili Pharmaceutical Co., Ltd.·Antibody-drug conjugate·PHASE1/PHASE2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

A Study of AP402 in HER2-Positive Patients With Locally or Advanced Solid Tumorsn = —

AP Biosciences Inc.·Monoclonal antibody·PHASE1/PHASE2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Chimeric Receptor T Cells With Trastuzumab in HER2+ Advanced Breast Cancer and Other Solid Tumorsn = —

National University Hospital, Singapore·HER2 CAR-T (adapter platform)·PHASE1/PHASE2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumorsn = —

Marengo Therapeutics, Inc.·Bispecific Other·PHASE1/PHASE2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)n = —

Beijing Biotech·Nk Cell Therapy·PHASE1/PHASE2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Dual-Target CAR-NK Cells Directed Against MSLN, EGFR, or HER2 in Advanced NSCLCn = —

Beijing Biotech·Nk Cell Therapy·PHASE1/PHASE2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Dual-target CLDN18.2/HER2 CAR-NK Cells for Advanced Gastric/GEJ Cancern = —

Beijing Biotech·Nk Cell Therapy·PHASE1/PHASE2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBCn = —

Beijing Biotech·Nk Cell Therapy·PHASE1/PHASE2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumorsn = —

Beijing Biotech·Universal adapter CAR-T platform·PHASE1/PHASE2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumorsn = —

Ensem Therapeutics·Bispecific Other·PHASE1/PHASE2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)n = —

Genmab·Antibody-drug conjugate·PHASE1/PHASE2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SYS6045 in Patients With HER2-Positive, Expressing, or Mutated Advanced Malignant Solid Tumorsn = —

CSPC Megalith Biopharmaceutical Co.,Ltd.·Small Molecule Other·PHASE1/PHASE2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumorsn = —

Hoffmann-La Roche·Small Molecule Other·PHASE1/PHASE2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignanciesn = —

Ascendis Pharma Oncology Division A/S·Small Molecule Other·PHASE1/PHASE2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Dual-Target CAR-NK Cells for Biomarker-Selected Advanced Colorectal Cancern = —

Beijing Biotech·Nk Cell Therapy·PHASE1/PHASE2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumorn = —

Yuhan Corporation·Monoclonal antibody·PHASE1/PHASE2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

A Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumorsn = —

Hutchmed·Monoclonal antibody·PHASE1/PHASE2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumorsn = —

Eli Lilly and Company·Kinase Inhibitor·PHASE1/PHASE2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Antibody-drug conjugateASX peers ›

13 activeexpand ›

NC
Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q)
Phase 2
National Cancer Institute (NCI)·Active, not recruiting·Primary completion 9 Mar 2019·NCT04439110
A
A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations
Phase 2
AstraZeneca·Active, not recruiting·Primary completion 25 Jan 2023·NCT04639219
AP
A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)
Phase 2
Astellas Pharma Global Development, Inc.·Active, not recruiting·Primary completion 25 Feb 2025·NCT04225117
A
A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors
Phase 2
AstraZeneca·Recruiting·Primary completion 30 Oct 2025·NCT06271837
SA
A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
Phase 2
Seagen, a wholly owned subsidiary of Pfizer·Active, not recruiting·Primary completion 31 May 2026·NCT06003231
MS
Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers
Phase 2
Memorial Sloan Kettering Cancer Center·Active, not recruiting·Primary completion 1 Feb 2027·NCT02675829
MA
A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)
Phase 2
M.D. Anderson Cancer Center·Recruiting·Primary completion 1 Mar 2027·NCT05673928
A
A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors
Phase 2
AstraZeneca·Active, not recruiting·Primary completion 23 Mar 2027·NCT04482309
DS
A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)
Phase 2
Daiichi Sankyo·Recruiting·Primary completion 25 July 2028·NCT06330064
SA
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
Phase 2
Seagen, a wholly owned subsidiary of Pfizer·Recruiting·Primary completion 28 July 2029·NCT06157892
GS
Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors
PHASE1/PHASE2
Gilead Sciences·Active, not recruiting·Primary completion 1 May 2026·NCT05101096
SB
A Study of BL-M07D1 in Patients With a Variety of Solid Tumors Including Locally Advanced or Metastatic HER2-positive/Low-expressing Urinary and Gastrointestinal Tumors
PHASE1/PHASE2
Sichuan Baili Pharmaceutical Co., Ltd.·Recruiting·Primary completion 1 Dec 2026·NCT06031584
G
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
PHASE1/PHASE2
Genmab·Recruiting·Primary completion 1 July 2027·NCT05579366

Kinase InhibitorASX peers ›

10 activeexpand ›

NC
Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B)
Phase 2
National Cancer Institute (NCI)·Active, not recruiting·Primary completion 22 Jan 2021·NCT04439136
SA
Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations
Phase 2
Seagen, a wholly owned subsidiary of Pfizer·Active, not recruiting·Primary completion 1 Nov 2023·NCT04579380
JH
SHR-4602 for Injection in Subjects With HER2-expressing or -Mutated Unresectable or Metastatic Solid Tumors
Phase 2
Jiangsu HengRui Medicine Co., Ltd.·Not yet recruiting·Primary completion 1 Nov 2025·NCT06516926
C(
Neratinib Tablets Monotherapy for Advanced Solid Tumors With HER2 Mutations
Phase 2
Convalife (Shanghai) Co., Ltd.·Not yet recruiting·Primary completion 14 Feb 2026·NCT06519110
B
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Phase 2
Bayer·Recruiting·Primary completion 3 Feb 2027·NCT06760819
NC
Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)
Phase 2
National Cancer Institute (NCI)·Recruiting·Primary completion 20 Feb 2027·NCT06126276
BI
Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations
Phase 2
Boehringer Ingelheim·Recruiting·Primary completion 31 Dec 2027·NCT06581432
PM
Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
PHASE1/PHASE2
Phoenix Molecular Designs·Recruiting·Primary completion 1 Sept 2026·NCT04115306
O
Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
PHASE1/PHASE2
ORIC Pharmaceuticals·Recruiting·Primary completion 1 Sept 2026·NCT05315700
EL
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
PHASE1/PHASE2
Eli Lilly and Company·Recruiting·Primary completion 1 July 2030·NCT05768139

Fc Fusion ProteinASX peers ›

1 activeexpand ›

Class profileexpand ›

Description

Recombinant proteins that fuse a target-binding domain to an antibody Fc region, which extends half-life and aids purification. In retinal disease the dominant example is aflibercept (Eylea), a VEGF "trap" that sequesters VEGF-A and placental growth factor, delivered by intravitreal injection. Sozinibercept (OPT-302, Opthea) is a VEGF-C / VEGF-D trap designed to be added on top of standard anti-VEGF-A therapy to block the compensatory VEGF-C/D escape pathway, rather than used as a standalone agent.

Class benchmarks

The anti-VEGF biologic/Fc-fusion class is among the most commercially proven in medicine: aflibercept (Eylea and Eylea HD) and the bispecific faricimab (Vabysmo) anchor a multi-billion-dollar wet-AMD and diabetic macular oedema market alongside ranibizumab (Lucentis). Efficacy is read in best-corrected visual acuity (BCVA letter gain) and anatomic (retinal thickness) endpoints, and the current competitive frontier is durability — stretching the dosing interval to 12-16 weeks to cut injection burden. Sozinibercept's thesis is incremental letter gain on top of an anti-VEGF-A backbone; its pivotal Phase 3 programme (ShORe / COAST) is the gating readout for the combination approach.

Commercial track record

The commercial moat sits with the incumbents (Regeneron/Bayer, Roche/Novartis) through entrenched prescribing, biosimilar defence and durability positioning. A combination agent must show a clinically meaningful BCVA benefit over an already-effective monotherapy to justify a second injection and incremental cost — a high commercial bar even when the mechanism is sound.

Capital intensity

Standard recombinant biologic manufacturing; cost-of-goods is modest relative to price. The dominant economics are the size of the wet-AMD/DME market and the injection-burden dynamic, not production cost. Biosimilar entry on aflibercept is now compressing class pricing.

Regulatory posture

A well-templated path — BCVA non-inferiority or superiority versus an approved comparator on established precedent, with anatomic secondary endpoints. The specific risk for a combination add-on is that regulators and payers demand a clear incremental benefit over anti-VEGF-A monotherapy, so a numerically positive but small effect may clear approval yet struggle commercially.

Class sources (4)

Eylea (aflibercept) prescribing information · FDA · accessed 29 May 2026
Vabysmo (faricimab) prescribing information · FDA · accessed 29 May 2026
Opthea — sozinibercept (OPT-302) ShORe / COAST Phase 3 program · Opthea · accessed 29 May 2026
Wykoff CC et al — anti-VEGF durability in retinal disease (Ophthalmology review) · Ophthalmology · accessed 29 May 2026

AO
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
Phase 2
ALX Oncology Inc.·Recruiting·Primary completion 1 Dec 2027·NCT07007559